HRPC- TAX 327 data (Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.doi:10.1056/NEJMoa040720Tannock, Ian F.de Wit, RonaldBerry, William R.Horti, JozsefPluzanska, AnnaChi, Kim N.Oudard, StephaneThéodore, Christine...
多西他赛:TAX327研究 / SWOG9916研究 多西他赛(Docetaxel): 又名多烯紫杉醇,是一种紫衫烷类抗肿瘤药物,可通过破坏肿瘤细胞的微管结构,破坏肿瘤细胞的有丝分裂,达到抗肿瘤作用。多西他赛的细胞内浓度比紫杉醇高3倍,在细胞内滞留时间长,因此比紫杉醇具有更强的抗肿瘤活性。 药代动力学:多西他赛代谢产物75%从粪便排泄(...
shown PSA responses in up to 80 percent of patients.17-19 However, outcomes of single-group studies are subject to bias.20 We conducted a phase 3 study, the TAX 327 Study, comparing docetaxel (given either every three weeks or weekly) plus daily prednisone with mitoxantrone plus prednisone....
HRPC- TAX 327 data (Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The Macroeconomic Effects of Tax Changes: Estimates Based on a New Measure of Fiscal Shocks Effective tax rates in macroeconomics : Cross-country estimates of tax rates on factor incomes and ...
TAX-327: Docetaxel Boosts Quality of Life in Prostate Cancer Patients with Minimal PainMemoryMemory impairmentMedial Dorsal Nucleus记忆An abstract is unavailable.doi:10.1097/01.COT.0000303122.10451.f6Laino, CharleneOncology Times
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-1753.Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX...
多西他赛:TAX327研究 / SWOG9916研究 多西他赛(Docetaxel): 又名多烯紫杉醇,是一种紫衫烷类抗肿瘤药物,可通过破坏肿瘤细胞的微管结构,破坏肿瘤细胞的有丝分裂,达到抗肿瘤作用。多西他赛的细胞内浓度比紫杉醇高3倍,在细胞内滞留时间长,因此比紫杉醇具有更强的抗肿瘤活性。
T. Ian, Tolerability and efficacy of docetaxel in older men with metastatic castrate- resistant prostate cancer (mCRPC) in the TAX 327 trial, J. Geriatr. Oncol., 2014, 5, 119-126.Horgan AM, Seruga B, Pond GR, et al. Tolerability and efficacy of docetaxel in older men with metastatic ...
The median survival of the cohort was 21 months (docetaxel) and 19 months (mitoxantrone) at last follow-up. The predictive c-index of the TAX 327 nomogram was 0.66 (95% CI: 0.54-0.70). The calibration plot demonstrated that the 2-year survival rate was underestimated by the nomogram. ...
Prescribing of docetaxel for castrate-resistant prostate cancer has increased following publication of the TAX327 study and NICE recommendations